Novel Drugs and Devices to Lower Intraocular Pressure Market Overall Study Report 2020 - 2026 | Mati Therapeutics Inc, BioLight Lifesciences Ltd., IOPtima Ltd., Eye Sonix, Bausch & Lomb Inc

Global Novel Drugs and Devices to Lower Intraocular Pressure Market

Intraocular pressure is the pressure formed inside the eye. The aqueous humor of the ciliary body in the eye is responsible for the intraocular pressure. The production and removal rate of aqueous humor by the ciliary body determines the pressure in the eye. The presence of extra fluid (aqueous humor) builds up pressure in the eye which can lead to glaucoma. There are two types of glaucoma, open-angle glaucoma and closed-angle glaucoma. Generally, tonometers are employed for determining the pressure caused in the eye.

Global Novel Drugs and Devices to Lower Intraocular Pressure Market Dynamics

Approval of drugs and devices associated with the treatment of glaucoma from various regulatory bodies is expected to boost the global novel drugs and devices to lower intraocular pressure market growth over the forecast timeframe. For instance, in May 2019, Ivantis Inc., received an approval from the U.S. Food and Drug Administration (FDA) for Hydrus microstent. It is a device used in minimally invasive glaucoma surgery. It is developed to lower eye pressure in patients with open angle glaucoma.

Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2670

Furthermore, in September 2018, Sun Pharmaceuticals Industries Ltd. received an approval from U.S. FDA for Xelpros (latanoprost ophthalmic emulsion) for treatment of glaucoma. It reduces the elevated intraocular pressure in the eye and has been designed with the help of Swollen Micelle Micro emulsion technology. Frequent approvals of drugs and devices is expected to accelerate global novel drugs and devices to lower intraocular pressure market growth.

The key market players are focused on monitoring the post-marketing results of approved drugs and devices for the treatment of glaucoma (Intraocular pressure), which is therefore expected to drive the global novel drugs and devices to lower intraocular pressure market development. For instance, Rhopressa, manufactured by Aerie Pharmaceuticals, was originally approved in December 2017 by U.S. Food and Drug Administration (FDA). The company is now studying the Rhopressa drug (Netarsudil ophthalmic solution) for its pharmacovigilance studies. The drug is presently being studied for its long-term effects on patients with open angle glaucoma and ocular hypertension. The study is expected to be completed by September 2019. Such developments are expected to drive the global novel drugs and devices to lower intraocular pressure market growth.

However, various side effects of glaucoma medications are expected to hinder growth of the global novel drugs and devices to lower intraocular pressure market. Side effects of medications used for the treatment of glaucoma, such as Rhopressa, include internal bleeding, corneal deposits, and stinging. Also, the cost of these medications is very high. For instance, 2.5 milliliter's of Rhopressa (Netarsudil ophthalmic solution) costs around US$269. Hence, these factors are expected to restrain the global novel drugs and devices to lower intraocular pressure market growth.

Global Novel Drugs and Devices to Lower Intraocular Pressure Market Regional Analysis

North America is expected to dominate the global novel drugs and devices to lower intraocular pressure market during the forecast period. Factors such as government initiatives expected to augment the North America novel drugs and devices to lower intraocular pressure market growth. For instance, in January 2019, Glaucoma Research Foundation, U.S., formed a team called Catalyst for a Cure. The investigators are working together to understand the exact cause of vision loss in glaucoma patients, and potential targeted therapies for the prevention and treatment of glaucoma. As a result, this factor is expected to support the global novel drugs and devices to lower intraocular pressure market growth.

Purchase Report Here @ https://www.coherentmarketinsights.com/insight/buy-now/2670

Key Players

Some of the major players operating in the global novel drugs and devices to lower intraocular pressure market include Mati Therapeutics Inc., BioLight Lifesciences Ltd., IOPtima Ltd., Eye Sonix, Bausch & Lomb Inc., Sun Pharmaceutical Industries Ltd., Allergan, Alcon Inc., Glaukos Corporation, and Pfizer Inc.

Market Taxonomy

By Treatment Type,
o Drugs
o Rhopressa
o Roclatan
o Xelpros
o Vyzulta
o Others
o Devices
o Implant
o Therapeutic Ultrasound
o Others
By Distribution Channel,
o Hospitals & Clinics
o Retail Channel
o Online Channel
By Region,
o North America
o Latin America
o Europe
o Asia Pacific
o Middle East
o Africa

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.